Seoul, South Korea

Yong Jin Lee

This inventor holds 2 USPTO granted patents. Top assignees: Abion Inc., Genopharm Inc., Seoul National University. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yong Jin Lee. Retrieved from https://idiyas.com/inventor/yong-jin-lee-rrlxm490

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 5.0


Company Filing History:


Years Active: 2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Yong Jin Lee: Innovator in mRNA Technology

Introduction

Yong Jin Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of mRNA technology. His innovative work has the potential to impact various medical applications.

Latest Patents

Yong Jin Lee holds a patent for an invention titled "In-Vitro Transcript mRNA and Pharmaceutical Composition Comprising Same." This patent represents a crucial advancement in the field of pharmaceuticals and biotechnology.

Career Highlights

Throughout his career, Yong Jin Lee has worked with notable organizations, including Abion Inc. and Seoul National University. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Yong Jin Lee has collaborated with Young Key Shin, further enhancing his research and development efforts in mRNA technology.

Conclusion

Yong Jin Lee's innovative work in mRNA technology and his contributions to the biotechnology field highlight his role as a significant inventor. His patent and collaborations reflect his commitment to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…